XNAS
INCR
Market cap63mUSD
Oct 08, Last price
5.03USD
1D
-1.95%
1Q
3.71%
Jan 2017
-98.09%
IPO
-95.09%
Name
InterCure Ltd
Chart & performance
P/E
—
P/S
0.67
EPS
—
Div yield, %
—
Shrs. gr., 5y
-14.86%
Rev. gr., 5y
32.96%
Revenues
270m
+13.13%
Net income
-36m
L-47.33%
CFO
17m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to production, marketing, and distribution of medical cannabis products. The company's product line features dried cannabis flowers and an oil-based cannabis extract. Additionally, InterCure allocates investments to the biomedical sector. Established in 1994, the firm's main headquarters are situated in Herzliya, Israel.
Key people
Vice President - Finance · since 2019
Internal Auditor · since 2014
Avner Barak
Director · since 2019
Director · since 2012
Chief Executive Officer, Director · since 2019
Director · since 2011
Lennie Grinbaum Michelson
External Director · since 2015
Gideon Hirschfeld
External Director · since 2018
Independent Director · since 2014
Legal address
85 MEDINAT HAYEHUDIM ST
10TH FLOOR
HERZLIYA, TA 4676670
IL
10TH FLOOR
HERZLIYA, TA 4676670
IL
Headquarters
11 USSISHKIN STREET
HADERA, HA 3844346
IL
HADERA, HA 3844346
IL
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||